Methylenetetrahydrofolate reductase C677T polymorphism: Association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in Greek patients

Pediatric Blood and Cancer

Volumn 47, Issue 2, 2006, Pages 147-151

  Chatzidakis, Konstantinos ^a   Goulas, Antonis ^a,d   Athanassiadou Piperopoulou, Fani ^b   Fidani, Liana ^a   Koliouskas, Dimifrios ^c   Mirtsou, Vassiliki ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c Aristotle University of Thessaloniki   (Greece)

^d NONE   (Greece)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; MTHFR gene polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE AMINOTRANSFERASE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; FOLINIC ACID; IFOSFAMIDE; MERCAPTOPURINE; MESNA; METHOTREXATE; PREDNISONE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESPONSE; ETHNOLOGY; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GREECE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ALANINE TRANSAMINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; GENOTYPE; GREECE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 33745778445     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20574     Document Type: Article

References (20)

1. Ueland PM, Hustad S, Schneede J, et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201.
2. Franco RF, Simoes BP, Tone LG, et al. The methylenetetrahydrofolate reductase C677T polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br J Haematol 2001;115:616-618.
3. Wiemels JL, Smith RN, Taylor GM, et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA 2001;98:4004-4009.
4. Krajinovic M, Lamothe S, Labuda D. et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 2004;103:252-257.
5. Skibola CF, Smith MT, Kane E, et al. Polymorhisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999;96:12810-12815.
6. Deligezer U, Akisik E, Dalay N. Genotyping of the MTHFR gene polymorphism, C677T in patients with leukemia by melting curve analysis. Mol Diag 2003;7:181-185.
7. Gemmati D, Ongaro A, Scapoli GL, et al. Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphomain adults. Cancer Epidemiol Biomarkers Prev 2004;13:787-794.
8. Chiusolo P, Reddiconto G, Cimino G, et al. Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population. Haematologica 2004;89:139-144.
9. Taub JW, Matherly LH, Ravindranath Y, et al. Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. Leukemia 2002;16:764-765.
10. Bernbeck B, Mauz-Korholz C, Zotz RB, et al. Methylenetetrahydrofolate reductase gene polymorphism and glucocorticoid intake in children with ALL and aseptic osteonecrosis. Klin Padiatr 2003;215:327-331.
11. Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics and neurotoxicity in children with leukemia. J Clin Oncol 2003;21:3084-3091.
12. Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004;4:66-72.
13. Chiusolo P, Reddiconto G, Casorelli I, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002;13:1915-1918.
14. Lambropoulos AF, Agorastos T, Foka ZJ, et al. Methylenetetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia. Cancer Lett 2003;191:187-191.
15. van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-2530.
16. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004;75:274-281.
17. Bostrom BC, Erdmann GR, Kamen BA. Systemic methotrexate exposure is greater after intrathecal than after oral administration. J Pediatr Hematol Oncol 2003;25:114-117.
18. Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used in the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12:183-190.
19. Aplenc R, Thompson J, Han P, et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005;65:2482-2487.
20. de Jonge R, Hooijberg JH, van Zelst BD, et al. Effect of polymorphisms in folate-related genes on in-vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 2005; [Epub ahead of print].